(Q34979794)

5 August 2017

1 reference

title

Biochemotherapy for advanced melanoma. (English)

1 reference

5 August 2017

Antonio C Buzaid

1

1 reference

5 August 2017

publication date

1 October 2002

1 reference

Critical Reviews in Oncology Hematology

5 August 2017

published in

1 reference

5 August 2017

volume

44

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

103-108

1 reference

5 August 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

Strategies for combining chemotherapy and biotherapy in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900223-2

7 January 2021

10.1016/S1040-8428(01)00223-2

Identifiers

DOI

1 reference

5 August 2017

1 reference